Fanny Chasseloup
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fanny Chasseloup has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Peter Kamenický
Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction , Le Kremlin-Bicêtre
4 shared publications Jacques Young
AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin Bicêtre, France
2 shared publications- Philippe Chanson
Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d’Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l’Hypophyse (HYPO) , Le Kremlin-Bicêtre 94275
2 shared publications Sylvie Salenave
AP-HP, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin Bicêtre, France
2 shared publicationsA. Guiochon-Mantel
Université Paris-Saclay, Inserm « physiologie et physiopathologie Endocriniennes », AP–HP, hôpital de Bicêtre, service de génétique moléculaire, Le Kremlin-Bicêtre, France
1 shared publicationA. Proust
Université Paris-Saclay, AP–HP, hôpital de Bicêtre, service de génétique Moléculaire, Le Kremlin-Bicêtre, France
1 shared publication
Latest Publications
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Pathogénie moléculaire de l'hyperplasie surrénalienne GIP-dépendante et du comportement invasif des adénomes hypophysaires
Partie I – L’HBMS GIP-dépendante est secondaire à l’expression illégitime du récepteur du GIP (GIPR) dans les lésions surrénaliennes. La nature bilatérale de cette pathologie suggère une prédisposition génétique. Notre objectif était d’identifier le mécanisme moléculaire à l’origine de l’expression ectopique surrénalienne du GIPR. Pour cela, nous avons mené une étude de cohorte et nous avons séquencé l’ADN germinal et somatique issu de surrénalectomie de 17 patients ayant une forme familiale ou sporadique d’HBMS GIP-dépendante. Nous avons réalisé des analyses transcriptomiques dans les échantillons surrénaliens et des analyses fonctionnelles in vitro afin de caractériser les anomalies génétiques identifiées dans des cellules corticosurrénaliennes humaines. Nous avons identifié des variants germinaux pathogènes du gène codant la lysine déméthylase 1A (KDM1A) chez les 17 patients étudiés et nous avons retrouvé une perte de bras court du chromosome 1 porteur du gène KDM1A dans les lésions surrénaliennes entrainant ainsi la perte complète de l’expression surrénalienne de KDM1A. L’étude par RNA-seq a permis d’identifier une régulation différentielle des récepteurs couplés aux protéines G chez les patients porteurs d’un variant de KDM1A parmi lesquels GIPR était le plus surexprimé. L’inhibition pharmacologique in vitro et le knock-out de KDM1A par l’approche CRISPR-Cas9 dans des cellules corticosurrénaliennes humaines entraînaient une augmentation significative de l’expression du GIPR. Nous avons pu montrer que l’HBMS avec expression illégitime du GIPR est une maladie génétique liée à une inactivation en deux étapes de KDM1A selon un modèle de gène suppresseur de tumeur. Partie II : L’envahissement des structures adjacentes, notamment des sinus caverneux par les adénomes hypophysaires limite le résultat du traitement chirurgical. Notre objectif était d’identifier les acteurs moléculaires responsables de l’invasion du sinus caverneux par les adénomes hypophysaires. Pour cela, nous avons comparé par RNA-seq les profils d’expression génique des portions non-invasives et des portions envahissant le sinus caverneux de 19 adénomes hypophysaires, et identifié une surexpression de la DPP4 (Dipeptidylpeptidase 4) dans les parties invasives. Nous avons étudié le rôle de l’inhibition pharmacologique de la DPP4 par la sitagliptine dans la migration et dans l'invasion de cellules hypophysaires murines in vitro. Nous avons mis au point un modèle d’adénomes hypophysaires invasifs murins par injection stéréotaxique orthotopique de cellules hypophysaires GC dans l’hypophyse de rats Wistar Furth. Après l’injection, les animaux étaient monitorés de manière hebdomadaire et le développement tumoral évalué toutes les deux semaines par imagerie par résonance magnétique 7Tesla. La moitié des animaux ont été traités par sitagliptine. L’inhibition de la DPP4 endogène par la sitagliptine diminuait l’invasion et la migration cellulaire in vitro dans deux lignées cellulaires hypophysaires murines. Nous avons également montré que les injections stéréotaxiques intra-hypophysaires conduisaient au développement de tumeurs en 7 semaines. L’étude du volume tumoral nous a permis d’identifier une diminution de la croissance tumorale et une amélioration de la survie dans un sous-groupe d’animaux traités par sitagliptine. Nous avons décrit la signature moléculaire des adénomes hypophysaires invasifs et montré une surexpression de la DPP4, dont nous avons prouvé le rôle dans la migration et l’invasion cellulaire in vitro. La sitagliptine in vivo permettait également de diminuer la croissance tumorale et d’améliorer la survie des animaux. Un plus grand nombre d’animaux seront nécessaires pour confirmer cette observation.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Pathogénie moléculaire de l'hyperplasie surrénalienne GIP-dépendante et du comportement invasif des adénomes hypophysaires
Partie I – L’HBMS GIP-dépendante est secondaire à l’expression illégitime du récepteur du GIP (GIPR) dans les lésions surrénaliennes. La nature bilatérale de cette pathologie suggère une prédisposition génétique. Notre objectif était d’identifier le mécanisme moléculaire à l’origine de l’expression ectopique surrénalienne du GIPR. Pour cela, nous avons mené une étude de cohorte et nous avons séquencé l’ADN germinal et somatique issu de surrénalectomie de 17 patients ayant une forme familiale ou sporadique d’HBMS GIP-dépendante. Nous avons réalisé des analyses transcriptomiques dans les échantillons surrénaliens et des analyses fonctionnelles in vitro afin de caractériser les anomalies génétiques identifiées dans des cellules corticosurrénaliennes humaines. Nous avons identifié des variants germinaux pathogènes du gène codant la lysine déméthylase 1A (KDM1A) chez les 17 patients étudiés et nous avons retrouvé une perte de bras court du chromosome 1 porteur du gène KDM1A dans les lésions surrénaliennes entrainant ainsi la perte complète de l’expression surrénalienne de KDM1A. L’étude par RNA-seq a permis d’identifier une régulation différentielle des récepteurs couplés aux protéines G chez les patients porteurs d’un variant de KDM1A parmi lesquels GIPR était le plus surexprimé. L’inhibition pharmacologique in vitro et le knock-out de KDM1A par l’approche CRISPR-Cas9 dans des cellules corticosurrénaliennes humaines entraînaient une augmentation significative de l’expression du GIPR. Nous avons pu montrer que l’HBMS avec expression illégitime du GIPR est une maladie génétique liée à une inactivation en deux étapes de KDM1A selon un modèle de gène suppresseur de tumeur. Partie II : L’envahissement des structures adjacentes, notamment des sinus caverneux par les adénomes hypophysaires limite le résultat du traitement chirurgical. Notre objectif était d’identifier les acteurs moléculaires responsables de l’invasion du sinus caverneux par les adénomes hypophysaires. Pour cela, nous avons comparé par RNA-seq les profils d’expression génique des portions non-invasives et des portions envahissant le sinus caverneux de 19 adénomes hypophysaires, et identifié une surexpression de la DPP4 (Dipeptidylpeptidase 4) dans les parties invasives. Nous avons étudié le rôle de l’inhibition pharmacologique de la DPP4 par la sitagliptine dans la migration et dans l'invasion de cellules hypophysaires murines in vitro. Nous avons mis au point un modèle d’adénomes hypophysaires invasifs murins par injection stéréotaxique orthotopique de cellules hypophysaires GC dans l’hypophyse de rats Wistar Furth. Après l’injection, les animaux étaient monitorés de manière hebdomadaire et le développement tumoral évalué toutes les deux semaines par imagerie par résonance magnétique 7Tesla. La moitié des animaux ont été traités par sitagliptine. L’inhibition de la DPP4 endogène par la sitagliptine diminuait l’invasion et la migration cellulaire in vitro dans deux lignées cellulaires hypophysaires murines. Nous avons également montré que les injections stéréotaxiques intra-hypophysaires conduisaient au développement de tumeurs en 7 semaines. L’étude du volume tumoral nous a permis d’identifier une diminution de la croissance tumorale et une amélioration de la survie dans un sous-groupe d’animaux traités par sitagliptine. Nous avons décrit la signature moléculaire des adénomes hypophysaires invasifs et montré une surexpression de la DPP4, dont nous avons prouvé le rôle dans la migration et l’invasion cellulaire in vitro. La sitagliptine in vivo permettait également de diminuer la croissance tumorale et d’améliorer la survie des animaux. Un plus grand nombre d’animaux seront nécessaires pour confirmer cette observation.
- 12 February 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (3)
Giant cell tumor of the sphenoid bone: a systematic literature review with illustrative cases
Giant cell tumors (GCTs) of the bone are typically benign but locally aggressive tumors usually affecting the long bones of young adults. Rarely, these tumors may arise in the skull, most often involving the sphenoid or temporal bones. Here, we performed a systematic literature review and identified 79 previously reported cases of GCTs of the sphenoid bone, and we added two illustrative cases of patients affected by this condition. The first patient, a 22-year-old woman, was treated with surgery and radiotherapy and has been followed up for 17 years without evidence of tumor recurrence. The second patient has been seen recently and was treated with two successive surgeries. These tumors usually occur between the second and the third decade of life and are more prevalent in women. Symptoms leading to diagnosis are related to local mass effect and include headache, third and sixth cranial nerve palsy, impaired facial sensitivity, diplopia, and decreased vision, and clinical manifestations of endocrine dysfunction may also be present. Imaging techniques usually depict an osteolytic lesion of the sphenoid bone extending to adjacent anatomical structures. Differential diagnoses include invasive pituitary adenomas, chordomas, chondrosarcomas, brown tumors, and giant cell reparative granulomas. The diagnosis is confirmed histologically, characterized by numerous osteoclast-like multinucleated giant cells, mononuclear cells, and stromal cells, the latter showing histone H3 G34W/R/V mutations on immunohistochemistry. Transsphenoidal surgery remains the first-line treatment, while radiotherapy or denosumab may be considered in cases of residual, progressive, or recurrent disease.
- 12 February 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (3)
Giant cell tumor of the sphenoid bone: a systematic literature review with illustrative cases
Giant cell tumors (GCTs) of the bone are typically benign but locally aggressive tumors usually affecting the long bones of young adults. Rarely, these tumors may arise in the skull, most often involving the sphenoid or temporal bones. Here, we performed a systematic literature review and identified 79 previously reported cases of GCTs of the sphenoid bone, and we added two illustrative cases of patients affected by this condition. The first patient, a 22-year-old woman, was treated with surgery and radiotherapy and has been followed up for 17 years without evidence of tumor recurrence. The second patient has been seen recently and was treated with two successive surgeries. These tumors usually occur between the second and the third decade of life and are more prevalent in women. Symptoms leading to diagnosis are related to local mass effect and include headache, third and sixth cranial nerve palsy, impaired facial sensitivity, diplopia, and decreased vision, and clinical manifestations of endocrine dysfunction may also be present. Imaging techniques usually depict an osteolytic lesion of the sphenoid bone extending to adjacent anatomical structures. Differential diagnoses include invasive pituitary adenomas, chordomas, chondrosarcomas, brown tumors, and giant cell reparative granulomas. The diagnosis is confirmed histologically, characterized by numerous osteoclast-like multinucleated giant cells, mononuclear cells, and stromal cells, the latter showing histone H3 G34W/R/V mutations on immunohistochemistry. Transsphenoidal surgery remains the first-line treatment, while radiotherapy or denosumab may be considered in cases of residual, progressive, or recurrent disease.
- 30 October 2024
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 25 (6) , 953-966
Prolactin: structure, receptors, and functions
Prolactin (PRL) is a 23-kDa protein synthesized and secreted by lactotroph cells of the anterior pituitary gland but also by other peripheral tissues. PRL binds directly to a unique transmembrane receptor (PRLR), and the JAK2/signal transducer and activator of transcription 5 (Stat5) pathway is considered the major downstream pathway for PRLR signaling. To a lesser extent, PRL may be cleaved into the shorter 16-kDa PRL, also called vasoinhibin, whose signaling is not fully known. According to rodent models of PRL signaling inactivation and the identification of human genetic alterations in PRL signaling, a growing number of biological processes are partly mediated by PRL or its downstream effectors. In this review, we focused on PRL structure and signaling and its canonical function in reproduction. In addition to regulating reproductive functions, PRL also plays a role in behavior, notably in initiating nurturing and maternal behavior. We also included recent insights into PRL function in several fields, including migraines, metabolic homeostasis, inflammatory and autoimmune disease, and cancer. Despite the complexity of understanding the many functions of PRL, new research in this field offers interesting perspectives on physiological and pathophysiological processes.
- 30 October 2024
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 25 (6) , 953-966
Prolactin: structure, receptors, and functions
Prolactin (PRL) is a 23-kDa protein synthesized and secreted by lactotroph cells of the anterior pituitary gland but also by other peripheral tissues. PRL binds directly to a unique transmembrane receptor (PRLR), and the JAK2/signal transducer and activator of transcription 5 (Stat5) pathway is considered the major downstream pathway for PRLR signaling. To a lesser extent, PRL may be cleaved into the shorter 16-kDa PRL, also called vasoinhibin, whose signaling is not fully known. According to rodent models of PRL signaling inactivation and the identification of human genetic alterations in PRL signaling, a growing number of biological processes are partly mediated by PRL or its downstream effectors. In this review, we focused on PRL structure and signaling and its canonical function in reproduction. In addition to regulating reproductive functions, PRL also plays a role in behavior, notably in initiating nurturing and maternal behavior. We also included recent insights into PRL function in several fields, including migraines, metabolic homeostasis, inflammatory and autoimmune disease, and cancer. Despite the complexity of understanding the many functions of PRL, new research in this field offers interesting perspectives on physiological and pathophysiological processes.
- 3 February 2024
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 85 (4) , 294-299
Diabetes insipidus: Vasopressin deficiency…
- 3 February 2024
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 85 (4) , 294-299
Diabetes insipidus: Vasopressin deficiency…
- 1 February 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (2) , 173-181
KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas
Paradoxical increase of GH following oral glucose load has been described in ∼30% of patients with acromegaly and has been related to the ectopic expression of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) in somatotropinomas. Recently, we identified germline pathogenic variants and somatic loss of heterozygosity of lysine demethylase 1A (KDM1A) in patients with GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome. The ectopic expression of GIPR in both adrenal and pituitary lesions suggests a common molecular mechanism. We aimed to analyze KDM1A gene sequence and KDM1A and GIPR expression in somatotroph pituitary adenomas. We conducted a cohort study at university hospitals in France and in Italy. We collected pituitary adenoma specimens from acromegalic patients who had undergone pituitary surgery. We performed targeted exome sequencing (gene panel analysis) and array-CGH on somatic DNA derived from adenomas and performed droplet digital PCR on adenoma samples to quantify KDM1A and GIPR expression. 146 patients with sporadic acromegaly were studied; 72.6% presented unsuppressed classical GH response, whereas 27.4% displayed a paradoxical rise in GH after oral glucose load. We did not identify any pathogenic variant in the adenomas of these patients. However, we identified a recurrent 1p deletion encompassing the KDM1A locus in 29 adenomas and observed a higher prevalence of paradoxical GH rise (p = 0.0166), lower KDM1A expression (4.47 ± 2.49 vs 8.56 ± 5.62, p < 0.0001) and higher GIPR expression (1.09 ± 0.92 vs 0.43 ± 0.51, p = 0.0012) in adenomas from patients with KDM1A haploinsufficiency compared to those with two KDM1A copies. Unlike in GIP-dependent primary bilateral macronodular adrenal hyperplasia, KDM1A genetic variations are not the cause of GIPR expression in somatotroph pituitary adenomas. Recurrent KDM1A haploinsufficiency, more frequently observed in GIPR-expressing adenomas, could be responsible for decreased KDM1A function resulting in transcriptional derepression on the GIPR locus.
- 1 February 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (2) , 173-181
KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas
Paradoxical increase of GH following oral glucose load has been described in ∼30% of patients with acromegaly and has been related to the ectopic expression of the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) in somatotropinomas. Recently, we identified germline pathogenic variants and somatic loss of heterozygosity of lysine demethylase 1A (KDM1A) in patients with GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing’s syndrome. The ectopic expression of GIPR in both adrenal and pituitary lesions suggests a common molecular mechanism. We aimed to analyze KDM1A gene sequence and KDM1A and GIPR expression in somatotroph pituitary adenomas. We conducted a cohort study at university hospitals in France and in Italy. We collected pituitary adenoma specimens from acromegalic patients who had undergone pituitary surgery. We performed targeted exome sequencing (gene panel analysis) and array-CGH on somatic DNA derived from adenomas and performed droplet digital PCR on adenoma samples to quantify KDM1A and GIPR expression. 146 patients with sporadic acromegaly were studied; 72.6% presented unsuppressed classical GH response, whereas 27.4% displayed a paradoxical rise in GH after oral glucose load. We did not identify any pathogenic variant in the adenomas of these patients. However, we identified a recurrent 1p deletion encompassing the KDM1A locus in 29 adenomas and observed a higher prevalence of paradoxical GH rise (p = 0.0166), lower KDM1A expression (4.47 ± 2.49 vs 8.56 ± 5.62, p < 0.0001) and higher GIPR expression (1.09 ± 0.92 vs 0.43 ± 0.51, p = 0.0012) in adenomas from patients with KDM1A haploinsufficiency compared to those with two KDM1A copies. Unlike in GIP-dependent primary bilateral macronodular adrenal hyperplasia, KDM1A genetic variations are not the cause of GIPR expression in somatotroph pituitary adenomas. Recurrent KDM1A haploinsufficiency, more frequently observed in GIPR-expressing adenomas, could be responsible for decreased KDM1A function resulting in transcriptional derepression on the GIPR locus.
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 550
Histone déméthylase KDM1A et régulation épigénétique des fonctions du pancréas endocrine chez le rat
- 19 September 2023
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 84 (5) , 550
Histone déméthylase KDM1A et régulation épigénétique des fonctions du pancréas endocrine chez le rat
- 1 October 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 261-262
Analyse du locus CYP21A2 par séquençage nouvelle génération : vers un nouveau standard pour le diagnostic moléculaire des blocs en 21-hydroxylase ?
- 1 October 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 261-262
Analyse du locus CYP21A2 par séquençage nouvelle génération : vers un nouveau standard pour le diagnostic moléculaire des blocs en 21-hydroxylase ?
- 31 March 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (6) , 1983-2005
Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing’s Disease With or Without an MEN4 Phenotype
Context Germline loss-of-function CDKN1B gene variants cause the autosomal dominant syndrome of multiple endocrine neoplasia type 4 (MEN4). Even though pituitary neuroendocrine tumors are a well-known component of the syndrome, only 2 cases of Cushing’s disease (CD) have so far been described in this setting. Aim To screen a large cohort of CD patients for CDKN1B gene defects and to determine their functional effects. Patients We screened 211 CD patients (94.3% pediatric) by germline whole-exome sequencing (WES) only (n = 157), germline and tumor WES (n = 27), Sanger sequencing (n = 6), and/or germline copy number variant (CNV) analysis (n = 194). Sixty cases were previously unpublished. Variant segregation was investigated in the patients’ families, and putative pathogenic variants were functionally characterized. Results Five variants of interest were found in 1 patient each: 1 truncating (p.Q107Rfs*12) and 4 nontruncating variants, including 3 missense changes affecting the CDKN1B protein scatter domain (p.I119T, p.E126Q, and p.D136G) and one 5’ untranslated region (UTR) deletion (c.-29_-26delAGAG). No CNVs were found. All cases presented early (10.5 ± 1.3 years) and apparently sporadically. Aside from colon adenocarcinoma in 1 carrier, no additional neoplasms were detected in the probands or their families. In vitro assays demonstrated protein instability and disruption of the scatter domain of CDKN1B for all variants tested. Conclusions Five patients with CD and germline CDKN1B variants of uncertain significance (n = 2) or pathogenic/likely pathogenic (n = 3) were identified, accounting for 2.6% of the patients screened. Our finding that germline CDKN1B loss-of-function may present as apparently sporadic, isolated pediatric CD has important implications for clinical screening and genetic counselling.
- 31 March 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (6) , 1983-2005
Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing’s Disease With or Without an MEN4 Phenotype
Context Germline loss-of-function CDKN1B gene variants cause the autosomal dominant syndrome of multiple endocrine neoplasia type 4 (MEN4). Even though pituitary neuroendocrine tumors are a well-known component of the syndrome, only 2 cases of Cushing’s disease (CD) have so far been described in this setting. Aim To screen a large cohort of CD patients for CDKN1B gene defects and to determine their functional effects. Patients We screened 211 CD patients (94.3% pediatric) by germline whole-exome sequencing (WES) only (n = 157), germline and tumor WES (n = 27), Sanger sequencing (n = 6), and/or germline copy number variant (CNV) analysis (n = 194). Sixty cases were previously unpublished. Variant segregation was investigated in the patients’ families, and putative pathogenic variants were functionally characterized. Results Five variants of interest were found in 1 patient each: 1 truncating (p.Q107Rfs*12) and 4 nontruncating variants, including 3 missense changes affecting the CDKN1B protein scatter domain (p.I119T, p.E126Q, and p.D136G) and one 5’ untranslated region (UTR) deletion (c.-29_-26delAGAG). No CNVs were found. All cases presented early (10.5 ± 1.3 years) and apparently sporadically. Aside from colon adenocarcinoma in 1 carrier, no additional neoplasms were detected in the probands or their families. In vitro assays demonstrated protein instability and disruption of the scatter domain of CDKN1B for all variants tested. Conclusions Five patients with CD and germline CDKN1B variants of uncertain significance (n = 2) or pathogenic/likely pathogenic (n = 3) were identified, accounting for 2.6% of the patients screened. Our finding that germline CDKN1B loss-of-function may present as apparently sporadic, isolated pediatric CD has important implications for clinical screening and genetic counselling.